Guangxi Sun
YOU?
Author Swipe
View article: Efficacy of Disitamab Vedotin and Immune Profiles in High‐Risk Non‐Muscle‐Invasive Bladder Cancer With HER2 Overexpression
Efficacy of Disitamab Vedotin and Immune Profiles in High‐Risk Non‐Muscle‐Invasive Bladder Cancer With HER2 Overexpression Open
View article: Two case reports of renal-splenic disease presenting as renal tumors or metastases, with a literature review
Two case reports of renal-splenic disease presenting as renal tumors or metastases, with a literature review Open
This article provides a comprehensive review of studies and case analyses on ectopic splenic tissue, with a particular focus on renosplenic disease. Ectopic splenic tissue refers to the abnormal non-physiological localization of spleen tis…
View article: Mapping the current research landscape of metformin in cancer based on bibliometric analysis
Mapping the current research landscape of metformin in cancer based on bibliometric analysis Open
View article: Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer
Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer Open
View article: First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials
First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials Open
Background: The emergence of immune checkpoint inhibitors and antibody–drug conjugates has revolutionized the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC). However, the optimal treatment s…
View article: Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets
Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets Open
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare yet highly lethal kidney cancer. To deepen our understanding of FH-deficient RCC, we conduct a comprehensive integrated genomic study. We analyze the associatio…
View article: The first birthday of OpenAI’s Sora: A promising but cautious future in medicine
The first birthday of OpenAI’s Sora: A promising but cautious future in medicine Open
View article: Correlation study of PBK/TOPK expression, prognosis, and immune infiltration in breast cancer
Correlation study of PBK/TOPK expression, prognosis, and immune infiltration in breast cancer Open
PDZ-binding kinase/T-lymphokine-activated killer-cell-originated protein kinase (PBK/TOPK) is a serine-threonine protein kinase. This study aimed to investigate the expression pattern, prognostic significance, and relationship with tumor i…
View article: The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis
The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis Open
View article: The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate Open
Background The prognostic value of the prostate adenocarcinoma (PAC) with ductal feature in patients with advanced prostate cancer treated with abiraterone acetate has not been scrutinized. This study aims to explore the predictive value o…
View article: Urogenital Manifestations in Mpox (Monkeypox) Infection: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Approaches
Urogenital Manifestations in Mpox (Monkeypox) Infection: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Approaches Open
Monkeypox (mpox), caused by mpox virus (MPXV) infection, reemerged in 2022 and still raises concerns globally. Abundant clinical data indicate that mpox is a sexually transmitted infection and that the urogenital system is the most frequen…
View article: Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor Open
Purpose To evaluate the efficacy and safety of extended immunotherapy in first-line immune checkpoint inhibitors (ICIs) - tyrosine kinase inhibitors (TKIs) combination treatment for advanced renal cell carcinoma (RCC). Patients and Methods…
View article: Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma
Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma Open
The WHO's classification of renal cell carcinoma (RCC) has identified loss of SMARCB1 as one of the driven mutations. Despite intensive postoperative interventions, the prognosis for SMARCB1-deficient medullary RCC remains poor, indicating…
View article: Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients
Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients Open
Background This study explored the value of intraductal carcinoma of the prostate (IDC‐P) in predicting the efficacy of abiraterone treatment in metastatic hormone‐sensitive prostate cancer (mHSPC) patients. Methods A retrospective study o…
View article: Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study – retrospective cohort
Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study – retrospective cohort Open
View article: Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma Open
View article: Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma Open
View article: The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis Open
Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear w…
View article: Supplementary Figure 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Figure 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Figure 4. Cell clusters in FH-deficient RCC stratified by immunotherapeutic response. (A) UMAP plot showing 23 cellclusters in FH-deficient RCC; (B) Bar plots showing tissue distribution of the eight main cell clusters using …
View article: Data from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Data from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Purpose:Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments and molecular correlates of benefits for FH-deficient RCC are currently lacking.Exp…
View article: Supplementary Table 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 4. Adverse events that occurred during treatment in 10% or more patients receiving first-line ICI+TKI.
View article: Supplementary Figure 2 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Figure 2 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response and duration of each patient receiving first-line systemic treatments; (B) Progre…
View article: Supplementary Table 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 5. Multivariate analysis of progression-free survival in patients treated with first-line ICI+TKI.
View article: Supplementary Table 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 4. Adverse events that occurred during treatment in 10% or more patients receiving first-line ICI+TKI.
View article: Supplementary Table 2 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 2 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 2. Baseline characteristics of patients with metastatic FH-deficient RCC.
View article: Supplementary Table 3 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 3 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 3. Survival outcomes for patients receiving different systemic treatments.
View article: Supplementary Figure 6 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Figure 6 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression of selected genes; (B) Correlations between the expression of six genes in the FH-deficient RCC immune signature and treatment re…
View article: Supplementary Figure 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Figure 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease and treatment flows. Overall survival (OS) for patients with synchronous and metachronous metastatic FH-deficient RCC in the overall…
View article: Supplementary Figure 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Figure 5 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Figure 5. Cell clusters and their distribution in a validation cohort by Dong et al.. (A) UMAP plot showing the sample distribution of T cells; (B) UMAP plot of all T cells collected from four samples; (C) Dot plot of marker …
View article: Supplementary Table 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Supplementary Table 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma Open
Supplementary Table 1. Baseline characteristics of patients with localized FH-deficient RCC.